Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: Implications for a possible physiological function of heparin cofactor II

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1740, Issue 1, 2005, Pages 45-53

  Tovar, Ana M F ^a   De Mattos, Diogo A ^a   Stelling, Mariana P ^a   Sarcinelli Luz, Branca S L ^a   Nazareth, Rômulo A ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Anticoagulant glycosaminoglycan; Dermatan sulfate; Heparan sulfate; Heparin cofactor II; Thrombosis; Vascular glycosaminoglycan

Indexed keywords

ANTITHROMBIN; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN COFACTOR II; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLOOD; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PURIFICATION; RAT; SAPHENOUS VEIN; SUBENDOTHELIUM; SULFATION; SYNTHESIS; THORACIC AORTA;

ANTICOAGULANTS; AORTA, THORACIC; DERMATAN SULFATE; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HEPARIN COFACTOR II; HEPARITIN SULFATE; HUMANS; SAPHENOUS VEIN; THROMBOSIS;

EID: 18844436263     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2005.02.008     Document Type: Article

References (49)

1. D.M. Tollefsen Antithrombin deficiency C.R. Scriver A.L. Beaudet W.S. Sly The Metabolism and Molecular Bases of Inherited Disease 8th ed. 2001 McGraw-Hill New York 4455 4471
2. H.H. van Bouen, and D.A. Lane Antithrombin and its inherited deficiency states Semin. Hematol. 34 1997 188 204
3. K. Ishiguro, T. Kojima, K. Kadomatsu, Y. Nakayama, A. Takagi, M. Suzuki, N. Takega, M. Ito, K. Yamamoto, T. Matsushita, K. Kusugami, T. Muramatsu, and H. Saito Complete antithrombin deficiency in mice results in embryonic lethality J. Clin. Invest. 106 2000 873 878
4. S.T. Olson, I. Björk, R. Sheffer, P.A. Craig, J.D. Shore, and J. Choay Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement J. Biol. Chem. 267 1992 12528 12538
5. P.S. Damus, M. Hicks, and R.D. Rosenberg Anticoagulant action of heparin Nature 246 1973 355 357
6. S. Haj Mohammadi, K. Enjyoji, M. Princivalle, P. Christi, M. Lech, D. Beeler, H. Rayburn, J.J. Schwartz, S. Barzegar, A.I. Agostini, M.J. Post, R.D. Rosenberg, and N.W. Shworak Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis J. Clin. Invest. 111 2003 989 999
7. D.M. Tollefsen Insight into the mechanism of action of heparin cofactor II Thromb. Haemost. 74 1995 1209 1214
8. K.A. Park, and D.M. Tollefsen The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation J. Biol. Chem. 260 1985 3501 3505
9. D.M. Tollefsen, C.A. Pestka, and W.J. Monafo Activation of heparin cofactor II by dermatan sulfate J. Biol. Chem. 258 1983 6713 6716
10. T.H. Tran, G.A. Marbet, and F. Duckert Association of hereditary heparin co-factor II deficiency with thrombosis Lancet 2 1985 413 414
11. P. Sié, D. Dupouy, J. Pichon, and B. Noneu Constitutional heparin co-factor II deficiency associated with recurrent thrombosis Lancet 2 1985 414 416
12. L. He, C.P. Vicent, R.J. Westrick, D.T. Eitzman, and D.M. Tollefsen Heparin cofactor II inhibits arterial thrombosis after endothelial injury J. Clin. Invest. 109 2002 213 219
13. A.M.F. Tovar, D.C.F. Cesar, G.C. Leta, and P.A.S. Mourão Age-related changes in populations of aortic glycosaminoglycans. Species with low affinity for plasma low-density lipoproteins, and not species with high affinity, are preferentially affected Arterioscler. Thromb. Vasc. Biol. 18 1998 604 614
14. G.C. Leta, P.A.S. Mourão, and A.M.F. Tovar Human venous and arterial glycosaminoglycans have similar affinity for plasma low-density lipoproteins Biochim. Biophys. Acta 1586 2002 243 253
15. L.E.M. Cardoso, and P.A.S. Mourão Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL Arterioscler. Thromb. 14 1994 115 124
16. T. Bitter, and H.M. Muir A modified uronic acid carbazole reaction Anal. Biochem. 4 1962 330 334
17. R.W. Farndale, D.J. Buttle, and A.J. Barret Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue Biochim. Biophys. Acta 883 1986 173 177
18. C.C. Werneck, M.S. Cruz, L.C.F. Silva, D.M.S. Villa-Verde, W. Savino, and P.A.S. Mourão Is there a glycosaminoglycan-related heterogeneity of the thymic epithelium? J. Cell. Physiol. 185 2000 68 79
19. S. Mauray, C. Sternberg, J. Theveniaux, J. Millet, C. Sinquin, J. Tapon-Bretaudiere, and A.M. Fischer Venous antithrombotic and anticoagulant activities of a fucoidan fraction Thromb. Haemost. 74 1995 1280 1285
20. G.M.T. Vogel, D.G. Meuleman, F.G.M. Bourgondiën, and P.M.J. Hobbelen Comparison of two experimental thrombosis models in rats. Effects of four glycosaminoglycans Thromb. Res. 54 1989 399 410
21. J.M. Herbet, A. Bernat, and J.P. Maffrand Importance of platelets in experimental thrombosis in the rat Blood 80 1992 2281 2286
22. M. Höök, I. Björk, J. Hopwood, and U. Lindahl Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin FEBS Lett. 66 1976 90 93
23. M. Lyon, J.A. Deakin, and J.T. Gallagher Liver heparan sulfate structure. A novel molecular design J. Biol. Chem. 269 1994 11208 11215
24. R.G. Pacheco, C.P. Vicente, P. Zancan, and P.A.S. Mourão Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm Blood Coagul. Fibrinolysis 11 2000 563 573
25. M.R. Buchanan, and S.J. Brister Anticoagulant and antithrombin effects of intiman, a heparin cofactor II agonist Thromb. Res. 99 2000 603 612
26. M.R. Buchanan, G.A. Maclean, and S.J. Brister Selective and sustained inhibition of surface-bound thrombin activity by intimatan/heparin cofactor II and its relevance to assessing systemic anticoagulant in vivo, ex vivo and in vitro Thromb. Haemost. 86 2001 909 913
27. L. Thumberg, G. Backström, and U. Lindahl Further characterization of the antithrombin-binding sequence in heparin Carbohydr. Res. 100 1982 393 410
28. U. Lindahl, G. Backström, and L. Thumberg The antithrombin-binding sequence in heparin. Identification of an essential 6-O-sulfate group J. Biol. Chem. 258 1983 9826 9830
29. H.E. Conrad Heparin-Binding Proteins 1998 Academic Press San Diego 254
30. C.T. Esmon, W. Ding, K. Yasuhiro, J.M. Gu, G. Ferrell, L.M. Regan, D.J. Stearns-Kurosawa, S. Kurosawa, T. Mather, Z. Laszik, and N.L. Esmon The protein C pathway: new insights Thromb. Haemost. 78 1997 70 74
31. A.M. Healy, H.B. Rayburn, R.D. Rosenberg, and H. Weiler Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system Proc. Natl. Acad. Sci. U. S. A. 92 1995 850 854
32. R.A. Shirk, N. Parthasarathy, J.D. San Antonio, F.C. Church, and W.D. Wagner Altered dermatan sulfate structure and reduced heparin cofactor II stimulating activity of biglycan and decorin from human atherosclerotic plaque J. Biol. Chem. 275 2000 18085 18092
33. N.T. Takamori, H. Azuma, M. Kato, S. Hashizume, K. Aihara, M. Akaike, K. Tamura, and T. Matsumoto High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention Circulation 109 2004 481 486
34. K. Yamanaga, T. Yuuki, M. Tsukada, H. Koshiba, T. Nakajima, K. Takechi, and N. Nakamura Heparin cofactor II inhibits thrombus formation in a rat thrombosis model Thromb. Res. 98 2000 95 101
35. J.K. Hennan, T.T. Hong, A.K. Shergill, E.M. Driscoll, A.D. Cardin, and B.R. Lucchesi Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury J. Pharmacol. Exp. Ther. 301 2002 1151 1156
36. E. Schonherr, H.T. Jarvelainen, M.G. Kinsella, L.J. Sandell, and T.N. Wight Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells Arterioscler. Thromb. 13 1993 1026 1036
37. M. Tammi, P.D. Seppala, A. Lenhtonen, and M. Mottonen Connective tissue components in normal and atherosclerotic human coronary arteries Atherosclerosis 29 1978 191 194
38. W.D. Wagner Proteoglycan structure and function as related to atherosclerosis Ann. N. Y. Acad. Sci. 454 1985 52 68
39. S.T. Cooper, L.L. Neese, M.N. DiCuccio, D.K. Liles, M. Hoffman, and F.C. Church Clin. Appl. Thromb./Hemost. 2 1996 185 191
40. D.J. Graham, and J.J. Alexander The effects of thrombin on bovine aortic endothelial and smooth muscle cells J. Vasc. Surg. 11 1990 307 313
41. C.A. McNamara, I.J. Sarembock, L.W. Gimple, J.W. Fenton, S.R. Coughlin, and G.K. Owens Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor J. Clin. Invest. 91 1993 94 98
42. L.B. Chen, and J.M. Buchanan Mitogenic activity of blood components: I. Thrombin and prothrombin Proc. Natl. Acad. Sci. U. S. A. 72 1975 131 135
43. K.C. Glenn, D.H. Carney, J.W. Fenton, and D.D. Cunningham Thrombin active site regions required for fibroblast receptor binding and initiation of cell division J. Biol. Chem. 255 1980 6609 6616
44. R. Bar-Shavit, A. Kahn, G.D. Wilner, and J.W. Fenton Monocyte chemotaxis: stimulation by specific exosite region in thrombin Science 220 1983 728 731
45. A.M. Crago, H.F. Wu, M. Hoffman, and F.C. Church Monocyte chemoattractant activity of Ser195 → Ala active site mutant recombinant alpha-thrombin Exp. Cell Res. 219 1995 650 656
46. D.M. Tollefsen Does heparin cofactor II modulate atherosclerosis and restenosis? Circulation 109 2004 2682 2684
47. S.R. Coughlin Protease-activated receptors in the cardiovascular system Cold Spring Harbor Symp. Quant. Biol. 67 2002 197 208
48. M.R. Buchanan, and S.J. Brister Inhibition of chronic vessel wall intimal hyperplasia following acute anticoagulant treatment: relative effects of heparin and dermatan sulphate Thromb. Res. 91 1998 157 167
49. K. Aihara, H. Azuma, N. Takamori, Y. Kanagawa, M. Akaike, M. Fujimura, T. Yoshida, S. Hashizume, M. Kato, H. Yamaguchi, S. Kato, Y. Ikeda, T. Arase, A. Kondo, and T. Matsumoto Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals Circulation 109 2004 2761 2765